Handelsavisen
prelaunch
Companies Healthcare 067630.KQ
06
067630.KQ KOSDAQ Pharmaceuticals

067630.Kq

$3 100,00
Open in Charts → Attach watcher ⌖
KRW
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
377,7B KRW
P/E
EV / Rev
Div yield
Op margin
-53,5 %
ROE
-33,6 %
Net margin
-218,1 %
Debt / equity
0,54
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

The company operates in the pharmaceuticals industry, primarily generating revenue through the development, production, and sale of pharmaceutical products and related medical research.

Business. The company operates in the pharmaceuticals industry, primarily generating revenue through the development, production, and sale of pharmaceutical products and related medical research.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryPharmaceuticals
ActivityPharmaceuticals & Medical Research
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
not yet wired
Profitability
-33,6 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning 067630.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to 067630.KQ. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    The company operates in the pharmaceuticals industry, primarily generating revenue through the development, production, and sale of pharmaceutical products and related medical research.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryPharmaceuticals
    ActivityPharmaceuticals & Medical Research
    AI synthesis
    GENERATED

    The company's capital structure is characterized by a debt-to-equity ratio of 0.54, indicating a moderate reliance on debt financing. Its liquidity position is assessed as medium, with a current ratio of 0.58, suggesting limited short-term liquidity. The company's price-to-book ratio is 1.44, and its price-to-tangible-book ratio is also 1.44, indicating that the market values the company's equity at a premium to its book value. However, the company's negative net cash position after subtracting total debt raises concerns about its ability to meet short-term obligations.

    Profitability metrics show significant underperformance relative to industry norms. The company reported a net loss of 99,794,375,250 KRW, with a return on equity of -0.3356 and a return on assets of -0.2087. These figures indicate that the company is not generating returns for shareholders or effectively utilizing its assets. The operating income was -24,479,408,760 KRW, and the gross profit was -494,412,460 KRW, further highlighting the company's operational challenges.

    The company's revenue is not segmented by geographic regions or product lines in the available data, making it difficult to assess the concentration of its revenue sources. However, the negative operating cash flow of -22,933,098,770 KRW and the free cash flow of -120,626,115,320 KRW suggest that the company is not generating sufficient cash from operations to sustain its activities or fund growth initiatives.

    The company's growth trajectory is negative, with a net loss and declining profitability. The available data does not provide specific outlook figures for the current or next fiscal year, but the company's financial performance indicates a challenging environment. The capital expenditure of -25,942,074,830 KRW suggests that the company is not investing in new projects or expanding its operations, which could further hinder its growth prospects.

    The company's risk profile is elevated, with a medium liquidity risk and a low dilution risk. The negative net cash position after subtracting total debt is a key flag, indicating potential liquidity constraints. The company's valuation adjustments and risk factors suggest that investors should closely monitor its financial health and operational performance.

    Recent events and filings do not provide specific details about the company's strategic initiatives or operational changes. The available data does not include recent transcripts or filings that could provide insight into the company's management decisions or market conditions.

    Key takeaways
    • The company is experiencing significant financial losses, with a net loss of 99,794,375,250 KRW and negative returns on equity and assets.
    • The company's liquidity position is weak, with a current ratio of 0.58 and a negative net cash position after subtracting total debt.
    • The company is not generating positive cash flows from operations, with a negative operating cash flow of -22,933,098,770 KRW and a free cash flow of -120,626,115,320 KRW.
    • The company's capital structure is moderately leveraged, with a debt-to-equity ratio of 0.54.
    • The company's growth trajectory is negative, with no clear signs of improvement in profitability or cash flow generation.
    • The company's risk profile is elevated, with a medium liquidity risk and a low dilution risk.

    Bull / Bear case

    analysis pipeline
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $3 100,00
    Market cap
    $428.90B
    Enterprise value
    $575.97B
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    1.4x
    P / Tangible book
    1.4x
    Tangible book
    $297.35B
    Net cash
    -$147.07B
    Current ratio
    0.6
    Debt / equity
    0.5
    ROA
    -20.9%
    ROE
    -33.6%
    Cash conversion
    23.0%
    CapEx / revenue
    -56.7%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin-53,5 %Bottom quartile
    Net Margin-218,1 %Bottom quartile
    ROE-33,6 %Bottom quartile
    Capex / Rev-56,7 %Bottom quartile
    D/E0,54Below median
    Cash Conv0,23Bottom quartile

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Return On Equity
      net_income / total_equity
    • Price To Book
      market_price / (adjusted_book_value / shares_outstanding_diluted)
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Market Price
      input from market-data provider (delayed close or quote-shim mid)
    • Market Cap
      market_price * shares_outstanding_diluted
    • Ev To Revenue
      enterprise_value / revenue
    Source documents
    • 067630.KQ Market data — financials · 2026-05-26

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    067630.KQCanonical
    KOSDAQ · KRW

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    — missing data
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage